The Olivia Newton-John Cancer Research Institute (ONJCRI) is proud to introduce its new Scientific Advisory Committee (SAC) - a distinguished panel of six world-renowned experts in cancer research, immunology, and translational medicine. This powerhouse of scientific leadership will provide strategic direction, ensuring ONJCRI remains at the forefront of groundbreaking discoveries and transformative patient outcomes.
This significant milestone marks a new chapter for ONJCRI as it strengthens its commitment to driving research impact, fostering innovation, and accelerating the translation of discoveries from the laboratory to the clinic.
Guiding ONJCRI’s Vision for the Future
The SAC will play a pivotal role in shaping ONJCRI’s scientific strategy, identifying emerging research opportunities, and fostering global collaborations. Their collective expertise will drive advances in targeted therapies, immunotherapies, and precision medicine, ensuring that ONJCRI’s research translates into meaningful outcomes for people affected by cancer.
Professor Marco Herold, CEO of the ONJCRI, welcomed the new committee with enthusiasm:
“ONJCRI is entering an exciting era of growth and discovery, and the insights of our Scientific Advisory Committee will be invaluable. These global leaders bring diverse expertise and fresh perspectives that will help us push the boundaries of cancer research and deliver better, more tolerable, and more accessible treatments for cancer patients.”
Meet the Scientific Advisory Committee
Each SAC member is a leader in their field, bringing extensive experience in oncology, immunology, and translational research. Their commitment to advancing cutting-edge science and improving patient outcomes will be instrumental in shaping ONJCRI’s research priorities and maximising the impact of its discoveries.
Associate Professor Eugene Maraskovsky
Executive Director & Research Therapeutic Area Lead – Transplant & Immunology, CSL Limited
A global authority in immunology, translational research, and drug development, Associate Professor Maraskovsky has played a key role in developing novel immunotherapies for cancer and autoimmune diseases.
We welcome him as Chair of this new ONJCRI Scientific Advisory Committee and look forward to his leadership in advancing our mission.
“I’m very excited about working with the Scientific Advisory Committee to guide the ONJCRI into becoming a preeminent cancer research institute, where research, translation, and therapeutic evaluation result in the improved diagnosis, treatment and prevention of human cancers.”
Professor Sharon Lewin
Director, Peter Doherty Institute for Infection and Immunity
An internationally recognised expert in infectious diseases and immunology, Professor Lewin brings a unique perspective from her work at the Doherty Institute, where she has been instrumental in advancing translational medicine and global health strategies.
“I am most looking forward to supporting Marco in building an outstanding research institute of global significance – one that ensures discoveries at ONJCRI improve the lives of people with cancer. I hope to bring a complementary perspective from my experience leading the Doherty Institute.”
Professor Grant McArthur AO
Chief Executive Officer, Victorian Comprehensive Cancer Centre Alliance
A world leader in precision medicine and targeted cancer therapies, Professor McArthur has spearheaded major advancements in melanoma, immunotherapy, and molecular oncology.
“I am most looking forward to contributing to the groundbreaking research that drives improvements in patient care. Research-led advancements are essential to cancer control, and I’m excited to be part of a team that enhances outcomes through these contributions at ONJCRI.”
Professor Elizabeth Hartland
Director and CEO, Hudson Institute of Medical Research
Professor Hartland is a pioneering microbiologist and President of the Australian Association of Medical Research Institutes (AAMRI). Her leadership in medical research has driven scientific breakthroughs and advanced new treatments across multiple disciplines.
“I am honoured to be part of the ONJCRI Scientific Advisory Committee and look forward to engaging with researchers at the Institute to help achieve the best outcomes for people diagnosed with cancer.”
Professor David Huang
Lab Head, Walter & Eliza Hall Institute (WEHI)
A pioneer in cancer cell death research, Professor Huang’s discoveries have significantly influenced the development of targeted therapies for leukaemia and lymphoma.
“I love talking about science and interacting with colleagues to discuss ideas and possibilities for translating research findings into real-world impact for cancer patients.”
Professor Sherene Loi
Group Leader, Peter MacCallum Cancer Centre
Renowned for her expertise in breast cancer immunology and genomics, medical oncologist Professor Loi has led major international clinical trials and is committed to translating research into meaningful clinical applications.
“I’m looking forward to working with the team at ONJCRI and contributing to research that can make a real difference for cancer patients. It’s a great opportunity to collaborate and help advance new ideas in the field.”
Professor Damien Bolton
Director of Surgery, Austin Health
A leading expert in urology and oncology, Professor Bolton has made significant contributions to surgical innovation, clinical research, and patient care. His expertise spans urological cancers, translational medicine, and basic science research.
We welcome Professor Bolton as the Board Member Representative on the ONJCRI Scientific Advisory Committee and look forward to his valuable insights in guiding our research efforts.
“I look forward to the committee’s potential to expedite the pathway between laboratory research and clinical evaluation of treatments.”
Accelerating Innovation and Impact
ONJCRI is taking a bold step toward expanding its research capabilities and ensuring that scientific investment and discoveries lead to real-world impact.
As ONJCRI continues to grow, the insights, leadership, and expertise of these six distinguished scientists will help shape our future – paving the way for life-changing innovations in cancer care.
Stay connected for updates as the Scientific Advisory Committee works alongside ONJCRI researchers to transform cancer care and advance the development of more effective, tolerable, and accessible treatments for all.